Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property

Rapid Dose Therapeutics Releases Nicotine Business Update and Extends Collaboration with International Nicotine Partner

By The Northwire Desk — AI Analysis Oct 20, 2025 · 08:49 DOSE · 0.165 Rapid Dose Therapeutics Corp.
DOSE · Price

Executive Summary

  • Rapid Dose Therapeutics extended its exclusive pre‑commercialisation and development agreement with an international nicotine partner for a further seven months, representing up to CAD 1.8 million in potential payments.
  • The company submitted Health Canada applications for NicStrip™ nicotine products (1–4 mg) and is conducting a GCP pharmacokinetic study to benchmark absorption against combustible cigarettes.
  • Two international PCT patent applications covering dissolvable and non‑dissolvable nicotine oral strip formats were filed in May 2025, expanding the firm’s IP portfolio.

Key Details

  • Agreement Extension: Retroactive effective date June 19 2025; term extended seven months from execution; total potential consideration up to CAD 1.8 million, subject to termination provisions.
  • Regulatory Progress: Health Canada submission filed August 4 2025 for NicStrip™ in 1 mg, 2 mg, 3 mg and 4 mg strengths.
  • Clinical Evaluation: Ongoing pharmacokinetic (PK) study launched June 2025 under Good Clinical Practice to compare nicotine absorption of NicStrip™ with combustible cigarettes.
  • Patent Activity: Two PCT applications filed May 2025 covering both dissolvable and non‑dissolvable nicotine oral strip formats.
  • Product Highlights:
  • Fast‑dissolving oral thin film delivering nicotine via the oral mucosa.
  • Customizable strengths (1–12 mg), flavors, dissolution profiles.
  • Discreet packaging, minimal waste, positive consumer feedback on flavor and mouthfeel.
  • Market Context:
  • Canadian nicotine pouch market valued at USD 112.2 M in 2024; projected CAGR 4.7% (2025‑2030).
  • Global nicotine pouch market projected to grow from USD 5.39 B (2024) to USD 25.40 B (2030), CAGR ≈29.6%.
  • Modern oral nicotine products category forecast to rise from USD 6.8 B (2024) to USD 75.7 B (2034), CAGR ≈27.7%.

Notable Quotes

  • “This extension marks an important milestone in advancing NicStrip™ toward potential commercialization discussions with our international nicotine partner.” – Mark Upsdell, CEO
  • “The financial commitment embedded in this extension underscores the shared seriousness in exploring a pathway to market in a rapidly evolving nicotine alternatives sector.” – Jason Lewis, Senior Vice President
Read the original news release →

More from Rapid Dose Therapeutics Corp.

Apr 13, 2026 · 09:51

Manufacturing Upgrades Mask Capital Burn Risks Amid Debt Maturity

Production / Operations Apr 06, 2026 · 16:31

Rapid Dose’s routine interest‑payment share issuance underscores ongoing dilution pressure as debt terms remain burdensome.

Financings Mar 26, 2026 · 18:34

Rapid Dose talks up IP wins, market expansion

Production / Operations Mar 26, 2026 · 09:10

Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory

Production / Operations Mar 05, 2026 · 18:16

Rapid Dose receives Indian patent for QuickStrip

M&A / Property Mar 05, 2026 · 10:09

Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market

M&A / Property